Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645499/ |
| id |
pubmed-4645499 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-46454992015-11-20 Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) Powles, Thomas Nickles, Dorothee Van Allen, Eliezer Chappey, Colombe Zou, Wei Kowanetz, Marcin Kadel, Edward Denker, Mitchell Boyd, Zachary Vogelzang, Nicholas Kim, Joseph Bellmunt, Joaquim Loriot, Yohann Drake, Charles G O'Hear, Carol Fasso, Marcella Hegde, Priti Mariathasan, Sanjeev Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645499/ http://dx.doi.org/10.1186/2051-1426-3-S2-P83 Text en Copyright © 2015 Powles et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Powles, Thomas Nickles, Dorothee Van Allen, Eliezer Chappey, Colombe Zou, Wei Kowanetz, Marcin Kadel, Edward Denker, Mitchell Boyd, Zachary Vogelzang, Nicholas Kim, Joseph Bellmunt, Joaquim Loriot, Yohann Drake, Charles G O'Hear, Carol Fasso, Marcella Hegde, Priti Mariathasan, Sanjeev |
| spellingShingle |
Powles, Thomas Nickles, Dorothee Van Allen, Eliezer Chappey, Colombe Zou, Wei Kowanetz, Marcin Kadel, Edward Denker, Mitchell Boyd, Zachary Vogelzang, Nicholas Kim, Joseph Bellmunt, Joaquim Loriot, Yohann Drake, Charles G O'Hear, Carol Fasso, Marcella Hegde, Priti Mariathasan, Sanjeev Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) |
| author_facet |
Powles, Thomas Nickles, Dorothee Van Allen, Eliezer Chappey, Colombe Zou, Wei Kowanetz, Marcin Kadel, Edward Denker, Mitchell Boyd, Zachary Vogelzang, Nicholas Kim, Joseph Bellmunt, Joaquim Loriot, Yohann Drake, Charles G O'Hear, Carol Fasso, Marcella Hegde, Priti Mariathasan, Sanjeev |
| author_sort |
Powles, Thomas |
| title |
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) |
| title_short |
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) |
| title_full |
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) |
| title_fullStr |
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) |
| title_full_unstemmed |
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) |
| title_sort |
immune biomarkers associated with clinical benefit from atezolizumab (mpdl3280a; anti-pd-l1) in advanced urothelial bladder cancer (ubc) |
| description |
|
| publisher |
BioMed Central |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645499/ |
| _version_ |
1613501454313586688 |